Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 166
News
News | 02 February 2022

Windlas Biotech concludes SAHPRA audit with an all-clear sign

It will enable the company to branch out to new geographies and strengthen its presence in South Africa

News
News | 01 February 2022

Lupin signs deal with Axantia to market pegfilgrastim in Middle East and Africa

Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy

News
News | 01 February 2022

Budget 22-23: Healthcare sector applauds focus on mental health

A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook

News
News | 31 January 2022

Pharma industry seeks fiscal support to drive innovation

Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India

News
News | 31 January 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results

News
News | 31 January 2022

Granules Pharmaceuticals concludes USFDA audit with three minor observations

The audit is a PAI for two of its product applications filed from this facility

News
News | 31 January 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results

News
News | 31 January 2022

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.

Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021

News
News | 31 January 2022

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey

In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21

News
News | 29 January 2022

DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine

Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission

News
News | 29 January 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct

News
News | 28 January 2022

Lupin signs promotional agreement with Exeltis on SOLOSEC

SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment

News
News | 28 January 2022

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion

The companies will continue with their exclusive agreements, including commercialization of their current portfolio

News
News | 28 January 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021

News
News | 27 January 2022

Covaxin and Covishield granted conditional market approval

The vaccines are currently only authorised for emergency use in the country

News
News | 27 January 2022

Moderna working on Omicron-specific booster candidate

This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older

News
News | 27 January 2022

Mark Cuban’s online pharmacy set to disrupt drug prices in the US

Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals

News
News | 27 January 2022

Minimizing API losses critical to responsible pharma manufacturing

Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases

News
News | 26 January 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.

News
News | 26 January 2022

Torrent Pharmaceuticals consolidated PAT at Rs 249 cr

Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.

Startup

Digitization